Page last updated: 2024-09-04

moxifloxacin and Experimental Lung Inflammation

moxifloxacin has been researched along with Experimental Lung Inflammation in 47 studies

Research

Studies (47)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (42.55)	29.6817
2010's	17 (36.17)	24.3611
2020's	10 (21.28)	2.80

Authors

Authors	Studies
Amaral, K; Dzink-Fox, J; Fischer, E; Goldovitz, J; Manni, K; Neckermann, G; Osborne, CS; Pecanka, R; Ryder, NS; Yu, D	1
Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M	1
Lamb, YN; Lee, A; Shirley, M	1
Cheng, Y; Wang, X; Zhang, Y	1
Chen, M; Hu, X; Shi, M; Zhang, M	1
Cai, DH; Fang, XL; Wang, J	1
Fu, M; Jing, L; Liu, B; Liu, H; Lou, M; Wang, H; Xu, L; Zhang, W	1
Abushanab, L; Alshamayleh, N; Anzueto, A; Arabiat, H; Diab, A; Haddad, G; Jaber, W; Khalil, B; Kufoof, N; Momani, D; Mughrabi, M; Mulhem, A; Obaidat, M; Odat, E; Ramadan, M; Wadi Al Ramahi, J; Zahran, A	1
Liu, J; Lou, B; She, J; Zhou, B	1
Ansari, Y; Capewell, N; Hui, BTK; Liu, X	1
Asai, K; Imoto, W; Kakeya, H; Kaneko, Y; Kawaguchi, T; Kuwabara, G; Nakaie, K; Niki, M; Oshima, K; Shibata, W; Watanabe, T; Yamada, K; Yamairi, K	1
Chen, L; Du, X; Han, Y; Jian, Y; Xuan, J	1
Chopra, V; Conlon, A; Flanders, SA; Gandhi, T; Malani, AN; Vaughn, VM	1
Hidaka, T; Takaku, C	1
Akata, K; Awaya, Y; Choujin, Y; Inoue, N; Ishimoto, H; Kawajiri, T; Kawanami, Y; Kawanaml, T; Mukae, H; Nagata, S; Nishida, C; Noguchi, S; Obata, H; Ogoshi, T; Orihashi, T; Suzuki, Y; Taura, Y; Tokuyama, S; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C	1
Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z	1
Bulcun, E; Çimen, D; Ekici, A; Ekici, M; Güngör, Ö	1
Bezlepko, A; Iudina, L; Kondova Topuzovska, I; Kuzman, I; Marschall, HP; Petri, T; Rókusz, L	1
Brock, B; Hardlei, TF; Jensen-Fangel, S; Kragh Thomsen, M; Kreilgaard, M; Öbrink-Hansen, K; Petersen, E	1
Cai, X; Cui, J; Ni, W; Wei, C	1
Clemens, DL; Dillon, BJ; Horwitz, MA; Lee, BY; Li, Z; Zink, JI	1
England, BS; Twilla, JD; Van Berkel, MA	1
Deshpande, D; Ferro, BE; Gumbo, T; Mouton, JW; Pasipanodya, JG; Srivastava, S; van Ingen, J; van Soolingen, D	1
Koopmans, RP; Prins, JM	1
Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE	1
Becker, J; Chatzikyrkou, C; Clajus, C; Hafer, C; Hamwi, I; Kielstein, JT	1
Bauer, TT; Ernen, C; Hauptmeier, BM; Hecht, J; Lepper, PM; Nüesch, E; Ott, SR; Pletz, MW; Welte, T	1
Boussery, K; Colpaert, K; de Paepe, P; de Smet, J; Decruyenaere, J; van Bocxlaer, J	1
Berk, E; Berk, V; Bozkurt, O; Demiraslan, H; Inanc, M; Karaca, H; Ozkan, M	1
Rijnders, BJ	1
Corris, P; Duprat-Lomon, I; Höffken, G; Kubin, R; Muir, JF; Sagnier, PP; Torres, A	1
Iakovlev, VP; Polushkina, NR	1
Albanèse, J; Bruguerolle, B; Lacarelle, B; Leone, M; Martin, C; Sampol-Manos, E; Simon, N	1
Keating, GM; Scott, LJ	1
Hoepelman, I	1
Davis, SL; Delgado, G; McKinnon, PS	1
Niederman, MS	1
Bauer, TT; de Zeeuw, J; Ernen, C; Schlosser, BM; Schultze-Werninghaus, G; Thate-Waschke, I; Welte, T	1
Solnick, JV	1
Akyurek, O; Altin, T; Guldal, M; Karaoguz, R; Ongun Ozdemir, A; Ozcan, O; Turhan, S	1
Ruef, C	1
Hoeffken, G; Meyer, HP; Verhoef, L; Winter, J	1
Garau, J; Lode, H	1

Reviews

10 review(s) available for moxifloxacin and Experimental Lung Inflammation

Article	Year
Delafloxacin: A Review in Community-Acquired Pneumonia. Drugs, 2022, Volume: 82, Issue:8 Topics: Adult; Anti-Bacterial Agents; Asthma; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Pulmonary Disease, Chronic Obstructive	2022
A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature. BMC pulmonary medicine, 2022, Jul-19, Volume: 22, Issue:1 Topics: Drug Hypersensitivity Syndrome; Eosinophilia; Female; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia	2022
Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation. Clinical therapeutics, 2021, Volume: 43, Issue:11 Topics: Community-Acquired Infections; Cost-Benefit Analysis; Humans; Levofloxacin; Moxifloxacin; Pneumonia	2021
Emergency Department Management of a Myasthenia Gravis Patient with Community-Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis? The Journal of emergency medicine, 2016, Volume: 50, Issue:2 Topics: Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Disease Progression; Female; Fluoroquinolones; Humans; Minocycline; Moxifloxacin; Myasthenia Gravis; Pneumonia; Tigecycline	2016
[Moxifloxacin: results of clinical use]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2002, Volume: 47, Issue:10 Topics: Anti-Infective Agents; Aza Compounds; Bronchitis, Chronic; Clinical Trials as Topic; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Quinolines; Respiratory Tract Infections; Sinusitis; Skin Diseases, Bacterial; Treatment Outcome	2002
Moxifloxacin--a new fluoroquinolone antibacterial. Drug and therapeutics bulletin, 2004, Volume: 42, Issue:8 Topics: Anti-Bacterial Agents; Aza Compounds; Drug Administration Schedule; Drug Costs; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Quinolines; Randomized Controlled Trials as Topic; Respiratory Tract Diseases; Sinusitis	2004
Moxifloxacin: a review of its use in the management of bacterial infections. Drugs, 2004, Volume: 64, Issue:20 Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Biological Availability; Bronchitis, Chronic; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Half-Life; Humans; Intestinal Absorption; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia; Quinolines; Sinusitis; Tissue Distribution; Topoisomerase II Inhibitors	2004
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin]. Nederlands tijdschrift voor geneeskunde, 2004, Oct-23, Volume: 148, Issue:43 Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pneumonia; Quinolines; Respiratory Tract Infections	2004
Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jul-15, Volume: 41 Suppl 2 Topics: Aza Compounds; Community-Acquired Infections; Disease Management; Drug Resistance, Microbial; Fluoroquinolones; Humans; Infusions, Intravenous; Moxifloxacin; Pneumonia; Quinolines; Quinolones; Streptococcus pneumoniae; Treatment Outcome	2005
Improving care for patients with respiratory tract infections. Journal of chemotherapy (Florence, Italy), 2002, Volume: 14 Suppl 2 Topics: Anti-Infective Agents; Aza Compounds; Bronchitis; Chronic Disease; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Patient Satisfaction; Pneumonia; Quality of Health Care; Quinolines; Sinusitis	2002

Trials

5 trial(s) available for moxifloxacin and Experimental Lung Inflammation

Article	Year
Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Chinese medical journal, 2014, Volume: 127, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies	2014
Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. The European respiratory journal, 2012, Volume: 39, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Health Care Costs; Humans; Length of Stay; Macrolides; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines; Treatment Failure	2012
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. The European respiratory journal, 2003, Volume: 21, Issue:1 Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillins; Pneumonia; Quinolines	2003
Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:2 Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Bronchi; Female; Fluoroquinolones; Half-Life; Humans; Injections, Intravenous; Male; Moxifloxacin; Pneumonia; Quinolines; Respiration, Artificial	2004
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respiratory medicine, 2001, Volume: 95, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Confidence Intervals; Double-Blind Method; Female; Fluoroquinolones; Humans; Liver Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies; Quinolines; Recurrence; Treatment Outcome	2001

Other Studies

32 other study(ies) available for moxifloxacin and Experimental Lung Inflammation

Article	Year
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Acetamides; Amidohydrolases; Animals; Anti-Infective Agents; Female; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Peptides; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae; Thigh	2009
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis. International journal of environmental research and public health, 2022, 04-15, Volume: 19, Issue:8 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary	2022
Diagnosis and Analysis of Clinical Characteristics of Vector borne and zoonotic diseases (Larchmont, N.Y.), 2022, Volume: 22, Issue:10 Topics: Amides; Animals; Anti-Bacterial Agents; Chlamydophila psittaci; Fever; Moxifloxacin; Nucleic Acids; Pneumonia; Psittacosis; Retrospective Studies	2022
Successful treatment of Talaromyces marneffei pneumonia in a HIV-negative renal transplantation recipient: A case report. Medicine, 2022, Oct-07, Volume: 101, Issue:40 Topics: Antifungal Agents; HIV Infections; Humans; Kidney Transplantation; Moxifloxacin; Mycoses; Pneumonia; Tacrolimus; Talaromyces; Voriconazole	2022
Comprehensive clinical evaluation of moxifloxacin: A retrospective study. Medicine, 2023, Jun-02, Volume: 102, Issue:22 Topics: Fluoroquinolones; Hospitalization; Humans; Moxifloxacin; Pneumonia; Retrospective Studies	2023
Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin. Journal of infection in developing countries, 2018, 10-31, Volume: 12, Issue:10 Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Pneumonia; Retrospective Studies; Severity of Illness Index; Treatment Outcome	2018
Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy. Scientific reports, 2020, 03-10, Volume: 10, Issue:1 Topics: Adolescent; Adult; Anti-Bacterial Agents; Case-Control Studies; Community-Acquired Infections; Female; Humans; Male; Metabolome; Moxifloxacin; Pneumonia; Prognosis; ROC Curve; Severity of Illness Index; Young Adult	2020
Bilateral acute anterior uveitis and iris atrophy caused by moxifloxacin. BMJ case reports, 2020, Jun-30, Volume: 13, Issue:6 Topics: Acute Disease; Anti-Bacterial Agents; Atrophy; Humans; Iris; Male; Middle Aged; Moxifloxacin; Mydriasis; Pneumonia; Tomography, Optical Coherence; Treatment Outcome; Uveitis, Anterior	2020
A mouse model of rapidly progressive fatal haemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Journal of global antimicrobial resistance, 2020, Volume: 23 Topics: Animals; Anti-Bacterial Agents; Gram-Negative Bacterial Infections; Mice; Moxifloxacin; Pneumonia; Stenotrophomonas maltophilia	2020
The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 09-27, Volume: 69, Issue:8 Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Ciprofloxacin; Clostridium Infections; Cohort Studies; Drug Prescriptions; Drug Resistance, Bacterial; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Michigan; Moxifloxacin; Pneumonia; Retrospective Studies; Risk; Surveys and Questionnaires	2019
[Usefulness of moxifloxacin tablet on nursing and health care-associated pneumonia--a prospective study with a simple suspension method]. The Japanese journal of antibiotics, 2013, Volume: 66, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Enteral Nutrition; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies; Quinolines; Severity of Illness Index; Suspensions; Tablets	2013
[Efficacy and safety of moxifloxacin in patients with nursing and healthcare-associated pneumonia]. The Japanese journal of antibiotics, 2013, Volume: 66, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines	2013
Case of round pneumonia: pulmonary infarct and a rare situation that is similar with the lung cancer. The clinical respiratory journal, 2015, Volume: 9, Issue:4 Topics: Diagnosis, Differential; Fluoroquinolones; Humans; Levofloxacin; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Pneumonia; Pulmonary Infarction; Radiography, Thoracic; Treatment Outcome; Young Adult	2015
Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC pulmonary medicine, 2014, Jun-30, Volume: 14 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Europe, Eastern; Female; Fluoroquinolones; France; Hospitalization; Humans; Kazakhstan; Kyrgyzstan; Length of Stay; Male; Middle Aged; Middle East; Moxifloxacin; Pneumonia; Prospective Studies; Severity of Illness Index; Young Adult	2014
Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Chromatography, High Pressure Liquid; Community-Acquired Infections; Computer Simulation; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Moxifloxacin; Pneumonia; Young Adult	2015
A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Infectious diseases (London, England), 2015, Volume: 47, Issue:12 Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cross Infection; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Minocycline; Monte Carlo Method; Moxifloxacin; Pneumonia; Sputum; Stenotrophomonas maltophilia; Tigecycline	2015
Mesoporous Silica Nanoparticles with pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic Tularemia. ACS nano, 2015, Nov-24, Volume: 9, Issue:11 Topics: Animals; Benzimidazoles; Drug Delivery Systems; Fluoroquinolones; Francisella tularensis; Humans; Hydrogen-Ion Concentration; Macrophages; Mice; Microbial Viability; Moxifloxacin; Nanoparticles; Phosphorous Acids; Pneumonia; Porosity; Silicon Dioxide; Treatment Outcome; Tularemia	2015
Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:6 Topics: Anti-Bacterial Agents; Area Under Curve; Drug Administration Schedule; Drug Dosage Calculations; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method; Moxifloxacin; Nontuberculous Mycobacteria; Pneumonia	2016
[Novel side effects of moxifloxacin: making a balanced decision again]. Nederlands tijdschrift voor geneeskunde, 2008, Aug-23, Volume: 152, Issue:34 Topics: Adverse Drug Reaction Reporting Systems; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Hepatitis; Humans; Moxifloxacin; Pneumonia; Quinolines; Risk Assessment; Stevens-Johnson Syndrome; Treatment Outcome	2008
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Current medical research and opinion, 2010, Volume: 26, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Costs and Cost Analysis; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Outpatients; Pneumonia; Quinolines; Young Adult	2010
Biopsy proven acute interstitial nephritis after treatment with moxifloxacin. BMC nephrology, 2010, Aug-23, Volume: 11 Topics: Acute Disease; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Biopsy; Carcinoma, Non-Small-Cell Lung; Creatinine; Edema; Eosinophilia; Fluoroquinolones; Humans; Lung Neoplasms; Male; Moxifloxacin; Nephritis, Interstitial; Pneumonectomy; Pneumonia; Postoperative Complications; Prednisolone; Quinolines	2010
Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study. Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:11 Topics: Administration, Intravenous; Administration, Oral; Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Biological Availability; Creatine; Critical Illness; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pilot Projects; Pneumonia; Prospective Studies; Quinolines; Therapeutic Equivalency	2012
Moxifloxacin-associated neutropenia. Scandinavian journal of infectious diseases, 2013, Volume: 45, Issue:5 Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Leukocyte Count; Moxifloxacin; Neutropenia; Pneumonia; Quinolines	2013
Moxifloxacin for community-acquired pneumonia. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:1 Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Intensive Care Units; Moxifloxacin; Pneumonia; Quinolines; Randomized Controlled Trials as Topic	2003
[After stroke threatens pneumonia. Antibiotics to be given prophylactically?]. MMW Fortschritte der Medizin, 2004, Oct-28, Volume: 146, Issue:44 Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Clinical Trials as Topic; Fluoroquinolones; Humans; Moxifloxacin; Placebos; Pneumonia; Quinolines; Stroke; Time Factors	2004
Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jul-15, Volume: 41 Suppl 2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Chi-Square Distribution; Community-Acquired Infections; Economics, Pharmaceutical; Female; Fluoroquinolones; Hospitalization; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines; Treatment Outcome	2005
Cost analyses of community-acquired pneumonia from the hospital perspective. Chest, 2005, Volume: 128, Issue:4 Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Cohort Studies; Community-Acquired Infections; Comorbidity; Costs and Cost Analysis; Female; Fluoroquinolones; Germany; Hospitals, Community; Humans; Male; Moxifloxacin; Pneumonia; Quinolines; Smoking	2005
Treatment with moxifloxacin versus standard therapy for community-acquired pneumonia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jul-01, Volume: 43, Issue:1 Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Quinolines	2006
Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. The Canadian journal of cardiology, 2007, Volume: 23, Issue:11 Topics: Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bradycardia; Cardiac Pacing, Artificial; Female; Fluoroquinolones; Humans; Long QT Syndrome; Moxifloxacin; Pneumonia; Quinolines; Risk Factors; Syncope; Torsades de Pointes; Treatment Outcome	2007
Nosocomial pneumonia - are economical considerations important? Infection, 2007, Volume: 35, Issue:6 Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Cefuroxime; Cross Infection; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Quinolines	2007
Gatifloxacin and moxifloxacin: two new fluoroquinolones. The Medical letter on drugs and therapeutics, 2000, Feb-21, Volume: 42, Issue:1072 Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gastrointestinal Diseases; Gatifloxacin; Humans; Moxifloxacin; Pneumonia; Quinolines; Staphylococcus aureus	2000
Avelox. Respiratory antibiotic now in i.v. form. Nursing, 2002, Volume: 32, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Injections, Intravenous; Moxifloxacin; Pneumonia; Quinolines	2002